Galderma Group AG/Fr. GALD
1D1W1MYTD1Y5YMAX
Capital at risk
About Galderma Group AG
Galderma Group AG is a global dermatology company specializing in the research, development, and marketing of medical solutions in skin health. The company operates in the pharmaceuticals, medical devices, and consumer products segments, offering treatments for conditions like acne, rosacea, psoriasis, and other dermatological ailments. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma leverages an extensive global network to distribute its products across various regions. The company's strategic focus on dermatology enables it to maintain a robust portfolio of targeted therapies and skincare solutions that address both medical and aesthetic needs.
- Ticker
- Fr. GALD
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 7,676
- Headquarters
- Zug, Switzerland
- Website
- www.galderma.com
GALD Metrics
BasicAdvanced
CHF 36B
51.90
CHF 2.98
-0.11
CHF 0.35
0.23%
Price and volume
Market cap
CHF 36B
Beta
-0.11
52-week high
CHF 188.25
52-week low
CHF 130.20
Average daily volume
381K
Dividend rate
CHF 0.35
Financial strength
Current ratio
1.242
Quick ratio
0.903
Long term debt to equity
32.295
Total debt to equity
33.061
Dividend payout ratio (TTM)
12.05%
Interest coverage (TTM)
7.34%
Profitability
EBITDA (TTM)
1,131.808
Gross margin (TTM)
69.37%
Net profit margin (TTM)
14.57%
Operating margin (TTM)
19.10%
Effective tax rate (TTM)
8.29%
Revenue per employee (TTM)
CHF 628,780
Management effectiveness
Return on assets (TTM)
5.35%
Return on equity (TTM)
10.82%
Valuation
Price to earnings (TTM)
51.902
Price to revenue (TTM)
7.493
Price to book
4.4
Price to tangible book (TTM)
-25.18
Price to free cash flow (TTM)
41.83
Free cash flow yield (TTM)
2.39%
Free cash flow per share (TTM)
3.701
Dividend yield (TTM)
0.23%
Growth
Revenue change (TTM)
26.29%
Earnings per share change (TTM)
129.78%
Bulls say / Bears say
Galderma delivered record first-half 2026 sales of $3.134 billion, up 24.6% year over year at constant currency, with double-digit growth across geographies and all product categories. The company also raised its full-year sales guidance, supporting the case for continued earnings momentum. (Galderma)
Therapeutic Dermatology is gaining substantial traction: first-half sales rose 67.9% at constant currency, supported by Nemluvio’s strong launch and expanding reimbursement and regulatory coverage. Galderma reported approximately 42% U.S. paid new-patient share in prurigo nodularis and 9% in atopic dermatitis in mid-2026. (Galderma)
Profitability and balance-sheet metrics improved materially: first-half Core EBITDA grew 42.8% at constant currency, margin expanded to 25.6%, and net leverage declined to 1.2x. Lower financing costs, share repurchases and continued cash generation provide additional support for equity returns. (Galderma)
The FDA issued a Complete Response Letter for relabotulinumtoxinA/Relfydess, citing manufacturing-site observations and analytical-method optimization. This delays Galderma’s U.S. launch of a potentially important neuromodulator growth driver. (Reuters)
Management flagged a potentially more difficult second half of 2026 because of volatile macroeconomic conditions, possible consumer-demand deterioration and U.S. tariff exposure. Although guidance was raised, these factors could make the upgraded outlook harder to achieve. (Reuters)
Nemluvio’s gross-to-net pricing evolution and higher royalty rates are creating margin headwinds, while U.S. phasing effects unwound in Injectable Aesthetics during the second quarter. This raises execution risk as Galderma continues scaling its fastest-growing therapeutic franchise. (Galderma)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
Funds containing GALD
AllEURGBPUSD
Fund name | Fund size | Fr. GALD weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 2.11% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 2.11% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 1.96% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.52% |
iShares MSCI Europe ex-UK€IEUX | €1.5B | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.